A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT00606177
First received: January 19, 2008
Last updated: January 16, 2014
Last verified: January 2014
Results First Received: November 28, 2013  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Bipolar I Disorder
Interventions: Drug: Aripiprazole
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Aripiprazole

Patients who had completed the preceding study and demonstrated drug efficacy were the target.

Subjects were administered 24 ,12, or 30 mg/day of aripiprazole once daily for 154 days.

Placebo

Patients who had completed the preceding study and demonstrated drug efficacy were the target.

Subjects were administered placebo once daily for 154 days.


Participant Flow:   Overall Study
    Aripiprazole     Placebo  
STARTED     55     44  
COMPLETED     28     19  
NOT COMPLETED     27     25  
Adverse Event                 9                 5  
Lack of Efficacy                 3                 7  
Physician Decision                 1                 0  
Protocol Violation                 1                 4  
Withdrawal by Subject                 5                 6  
Progression to depressive phase                 6                 1  
Diabetic blood glucose level/ High HbA1c                 1                 1  
Change of residence or other commitments                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Full Analysis Population(FAS):Excluding 3 subject with GCP violation from the randomized subjects.

(Aripiprazole:1, Placebo:2)


Reporting Groups
  Description
Aripiprazole

Patients who had completed the preceding study and demonstrated drug efficacy were the target.

Subjects were administered 24 ,12, or 30 mg/day of aripiprazole once daily for 154 days.

Placebo

Patients who had completed the preceding study and demonstrated drug efficacy were the target.

Subjects were administered placebo once daily for 154 days.

Total Total of all reporting groups

Baseline Measures
    Aripiprazole     Placebo     Total  
Number of Participants  
[units: participants]
  54     42     96  
Age  
[units: years]
Mean ± Standard Deviation
  38.7  ± 11.95     37.8  ± 11.67     38.3  ± 11.78  
Age  
[units: participants]
     
<=18 years     0     1     1  
Between 18 and 65 years     54     41     95  
>=65 years     0     0     0  
Gender  
[units: participants]
     
Female     29     24     53  
Male     25     18     43  
Region of Enrollment  
[units: participants]
     
Taiwan     4     9     13  
China     9     9     18  
Japan     22     10     32  
Malaysia     4     6     10  
Indonesia     5     2     7  
Philippines     10     6     16  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Young Mania Rating Scale (YMRS)   [ Time Frame: Baseline (Day 1 of preceding study) , Day 154 or at discontinuation ]

2.  Secondary:   Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)   [ Time Frame: Baseline (Day 1 of preceding study), Day 154 or at discontinuation ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Director of Clinical Research and Development
Organization: Otsuka Pharmaceutical Co., Ltd.
phone: +81-3-6361-7366


No publications provided


Responsible Party: Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT00606177     History of Changes
Other Study ID Numbers: 031-06-004
Study First Received: January 19, 2008
Results First Received: November 28, 2013
Last Updated: January 16, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare